Global Consumer Continuous Glucose Monitoring (CGM) Market Strategic Research Report

The global consumer continuous glucose monitoring (CGM) market has emerged as one of the most commercially consequential segments within the broader diabetes care and metabolic health landscape. Valued at approximately USD 7.8 billion in 2024, the market encompasses wearable biosensor devices, transmitters, receiver hardware, and the associated software platforms that enable real-time interstitial glucose measurement without routine fingerstick calibration. The shift from hospital-grade CGM systems toward consumer-oriented, over-the-counter, and prescription retail channels has fundamentally altered the competitive structure of the industry, drawing medical device incumbents, technology companies, and venture-backed startups into sustained rivalry. Growing adoption among both insulin-dependent and non-insulin-dependent diabetic populations, alongside a fast-expanding segment of metabolically curious non-diabetic consumers, has broadened the total addressable market well beyond traditional clinical boundaries.

Three forces are principally responsible for the market's accelerating trajectory. First, the global diabetes burden continues to intensify: the International Diabetes Federation estimated 537 million adults living with diabetes in 2021, a figure projected to reach 783 million by 2045, creating structural demand for continuous monitoring solutions that outperform episodic blood glucose testing. Second, regulatory liberalization—most notably the U.S. Food and Drug Administration's 2023 clearance of the first over-the-counter CGM device—has materially lowered the barrier to consumer purchase, enabling direct retail distribution through pharmacy chains and e-commerce platforms that previously required a physician prescription. Third, the rise of personalized nutrition and metabolic fitness applications has generated demand from health-conscious non-diabetic consumers who use CGM data to optimize diet, exercise, and sleep, a segment that several leading manufacturers are actively targeting with dedicated product lines. The primary restraint on market expansion remains device cost and reimbursement variability: in many emerging economies, CGM sensors carry an out-of-pocket price that significantly exceeds the daily healthcare spending capacity of the average patient, limiting penetration despite high disease prevalence.

This report delivers a comprehensive quantitative and qualitative assessment of the global consumer CGM market across the 2025–2032 forecast horizon, grounded in a 2024 base year. It segments the market by sensor type, wear duration, connectivity platform, and end-use application; provides granular forecasts across five geographic regions and six priority countries; and profiles ten major commercial participants with analysis of revenue positioning, product portfolios, and strategic trajectories. The report is designed to serve corporate strategy teams evaluating portfolio expansion, investment analysts conducting sector due diligence, M&A advisors assessing acquisition targets, and procurement managers benchmarking supplier capabilities.